PA Media on MSN7h
GSK lifts long-term sales targets on new drug pipelineFailed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...
DPA International on MSN7h
Annual core operating profit increases for British pharma GSKAnnual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.
Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...
Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...
GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ... As on 31-12-2024, the company has a total of 16.94 Crore shares outstanding.GSK Pharma Share Price Today is Rs. 1960.40. On previous day, ...
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback